evipedia.ai
← Back

S. boulardii for Health & Longevity

Evidence Review created on 10/20/2026 using AI4L / Opus 5.5

Also known as: Saccharomyces boulardii, Saccharomyces cerevisiae var. boulardii, Saccharomyces boulardii CNCM I-745, CNCM I-745, CNCM I-1079, Florastor, Enterol, Perenterol, Ultra-Levure, Bioflor

Motivation

S. boulardii is a living yeast, a close relative of baker’s yeast, sold as a probiotic in capsules and powders. Unlike most probiotics, which are bacteria, it is a fungus, so common antibiotics do not kill it. It is thought to work inside the gut by neutralizing harmful microbes and their toxins and by supporting the gut lining.

The yeast was first taken from tropical fruit peel about a century ago and has long been sold in Europe as an over-the-counter remedy for diarrhea. It has since been tested in many clinical trials, most often for diarrhea linked to antibiotics or infections, and more recently for chronic bowel complaints. Interest has grown alongside wider attention to the community of microbes in the gut and its links to long-term health.

This review examines what the human evidence shows about the benefits and harms of the yeast for health-focused adults, how strong and how independent that evidence is, and which practical factors, such as dose, timing, product quality and the people for whom it is unsuitable, shape its use.

Benefits - Risks - Protocol - Conclusion

This section lists overview content from practitioners and narrative reviews that discuss S. boulardii in depth.

No relevant content was found from Peter Attia, Andrew Huberman or Lifespan.io; Rhonda Patrick’s only mention is a passing remark in a members-only Q&A, and Chris Kresser’s articles mention the yeast only briefly within broader antibiotic and probiotic topics, so none of these is listed. Only four items are listed because no fifth source discussing the yeast in depth was found.

Grokipedia

Saccharomyces boulardii

An AI-written encyclopedia overview of the yeast’s taxonomy, history, mechanisms, clinical uses and fungemia (yeast bloodstream infection) risk; useful for orientation but not a primary evidence source.

Examine

Saccharomyces cerevisiae

Examine’s supplement page for the yeast species, centered on its most-studied probiotic strain, S. cerevisiae var. boulardii, with graded evidence for diarrhea, irritable bowel symptoms and the ulcer-causing stomach bacterium H. pylori.

ConsumerLab

Probiotic Supplements Review (Including Pet Probiotics)

ConsumerLab has no article dedicated to S. boulardii; this broader review independently tests two S. boulardii products, Florastor and Jarrow Formulas Saccharomyces Boulardii + MOS, against their label claims. Full results require membership.

Systematic Reviews

This section lists systematic reviews and meta-analyses of S. boulardii, covering its main claimed benefits and its principal risk.

Mechanism of Action

S. boulardii is a live yeast that acts inside the gut rather than being absorbed into the body. Laboratory and animal work, summarized in a mechanism review by Czerucka and Rampal (both consultants to the manufacturer Biocodex), points to several actions:

  • Toxin neutralization: it secretes a protease (a protein-cutting enzyme) that degrades the toxins of Clostridioides difficile (a toxin-producing gut bacterium) and a phosphatase (an enzyme that strips phosphate groups) that inactivates endotoxin (a bacterial cell-wall toxin that triggers inflammation)
  • Pathogen binding: its cell wall traps harmful Escherichia coli and other bacteria
  • Gut lining and immune effects: it dampens NF-κB (a master switch for inflammatory genes), raises secretory IgA (the antibody that guards gut surfaces) and strengthens the seals between gut-lining cells
  • Buffering the microbiota: antibiotics cannot kill a yeast, so it persists during antibiotic courses and helps disturbed gut bacteria recover

Pharmacology:

  • Half-life: no classical half-life; stool levels rise with dose (Klein 1993), and it leaves stool 2–5 days after the last dose (French product label)
  • Selectivity and distribution: it stays inside the gut without permanent colonization, reaching the blood only in rare infections
  • Metabolism: it is not processed by liver enzymes; ampicillin raised its stool levels about 2.4-fold (Klein 1993), while antifungal drugs kill it

A competing view stresses that it is genetically a baker’s yeast strain (Saccharomyces cerevisiae) with transient, strain-specific effects that, per the same review, leave healthy people’s gut bacteria unchanged, limiting any general “gut optimization” role.

Historical Context & Evolution

In 1923 the French microbiologist Henri Boulard isolated the yeast from lychee and mangosteen peel in Indochina, reportedly after seeing local people chew the skins to control cholera-like diarrhea. Its original use was therefore as an antidiarrheal. The French company Biocodex developed it into a medicine, and it is still sold in France as the non-prescription antidiarrheal Ultra-Levure, according to the national medicines database.

Controlled research began in the 1980s. French tube-feeding trials were co-authored by Biocodex scientist H. Bléhaut, who also authored its human kinetics study, and a University of Washington group reported fewer cases of antibiotic-associated diarrhea in inpatients and fewer recurrences of C. difficile colitis. Trials then spread to travelers, children with gastroenteritis, H. pylori treatment and inflammatory bowel disease.

Two developments changed the picture. Genotyping studies, such as Edwards-Ingram 2007, showed the strain is a variety of S. cerevisiae, not a separate species, and from the late 1990s reports of yeast bloodstream infections in catheterized and intensive-care patients, including an intensive-care outbreak, led the French label to contraindicate such patients. Large independent trials in German and Italian inpatients then found no protection against antibiotic diarrhea, while meta-analyses pooling all trials still found an average benefit. Its move into health optimization reflects the broader microbiome boom and its unusual ability to survive antibiotics.

Expected Benefits

High 🟩 🟩 🟩

Prevention of Antibiotic-Associated Diarrhea ⚠️ Conflicted

Taking the yeast alongside antibiotics lowers the chance of antibiotic-associated diarrhea, likely by buffering the antibiotic-induced collapse of gut bacteria. A meta-analysis of 21 randomized trials found benefit in children and adults, with positive trials from independent groups led by Surawicz (Seattle), Kotowska (Warsaw) and Kabbani (Boston). However, the largest independent adult inpatient trials, by Ehrhardt (477 patients) and Pozzoni (elderly inpatients), and a Lewis trial in 69 patients over 65 found no effect. Net reading: a real average benefit that shrinks or disappears in low-risk adult inpatients.

Magnitude: Diarrhea in 8.5% with S. boulardii vs 18.7% with placebo or no treatment, pooled across 21 trials: RR (risk ratio, one group’s risk divided by the other’s) 0.47, 95% CI (confidence interval, the range likely to contain the true value) 0.38–0.57, NNT (number needed to treat for one person to benefit) 10. Ehrhardt found an HR (hazard ratio, the relative event rate over time) of 1.02 (95% CI 0.55–1.90).

Higher Helicobacter pylori Eradication as an Add-On to Therapy ⚠️ Conflicted

Adding the yeast to standard antibiotic-and-acid-suppressant regimens modestly raises H. pylori cure rates and lowers treatment side effects; eradication matters because the bacterium drives ulcers and stomach cancer. Independent trials led by Seddik (Rabat) and Yang (nine Chinese centers) found higher eradication, and meta-analyses by Szajewska, Zhou and Chang confirm the pooled gain. However, a 124-patient placebo-controlled trial by Cindoruk found no significant gain. Net reading: a small pooled gain that single trials are often too small to detect.

Magnitude: Eradication in 80% with S. boulardii vs 71% with the regimen alone (RR 1.11; 95% CI 1.06–1.17; 11 trials, 2,200 participants; Szajewska 2015); Chang 2026 reports RR 1.07 (95% CI 1.03–1.10) in adults, an absolute gain of 5.7 percentage points, NNT 18. Cindoruk 2007: 71% vs 59.7% with placebo (p, the probability of a result this large arising by chance, > 0.05).

Better Quality of Life in Irritable Bowel Syndrome

In diarrhea-predominant or mixed irritable bowel syndrome (recurrent abdominal pain with altered bowel habits), placebo-controlled trials led by Choi (Seoul; 67 patients, 4 weeks) and Abbas (Karachi; 72 patients, 6 weeks, both arms on psyllium, a plant-seed fiber supplement) each found greater improvement on a validated irritable bowel quality-of-life questionnaire (IBS-QOL) with the yeast. Neither showed a consistent advantage on bowel symptoms, which a 2026 strain-specific meta-analysis rated conflicting without pooling quality of life. Both trials were small and short.

Magnitude: IBS-QOL score improved 15.4% vs 7.0% with placebo (between-group p < 0.05; no confidence interval reported; Choi 2011); symptom composite scores fell to a similar extent in both groups.

Medium 🟩 🟩

Prevention of Traveler’s Diarrhea

Taken before and during travel, the yeast reduced travelers’ diarrhea in a placebo-controlled trial of 3,000 Austrian travelers by Kollaritsch and colleagues, with a larger effect at the higher dose and a tendency toward stronger protection in North Africa and Turkey. No independent replication was found.

Magnitude: Diarrhea in 28.7% with S. boulardii vs 39.1% with placebo among 1,016 travelers from the Kollaritsch trial, as tabulated in a review by Brown & Valiere 2004 (between-group p < 0.05; no confidence interval reported); protection rose with dose and adherence.

Relief of Small Intestinal Bacterial Overgrowth

In 33 patients with decompensated cirrhosis (advanced liver scarring with complications), a single-blind placebo-controlled trial by Efremova (Moscow; funded by the Biocodex Microbiota Foundation) found more overgrowth clearance with the yeast. In systemic sclerosis (an autoimmune disease that slows gut movement), García-Collinot (Mexico City) reported more clearance than with metronidazole (an antibiotic) alone. In diarrhea-predominant irritable bowel syndrome, Bustos Fernández (Buenos Aires) reported larger symptom and breath-test improvements than diet advice alone. These two were open-label (unblinded).

Magnitude: Overgrowth absent after 3 months in 80.0% vs 23.1% with placebo (p = 0.002; no confidence interval reported; Efremova 2024); cleared in 33% with the yeast alone, 55% with yeast plus metronidazole and 25% with metronidazole alone after 2 months (open-label; between-arm statistics for clearance not reported); symptom score fell 134 vs 93 points with diet advice alone (not compared between groups).

Reduced Knee Osteoarthritis Pain

In 70 overweight or obese adults with knee osteoarthritis, a 12-week triple-blind trial by Dolatkhah (Tabriz) found less pain, lower analgesic (pain medication) use and lower hs-CRP (high-sensitivity C-reactive protein, a blood marker of inflammation) than placebo. A gut-to-joint inflammation link is plausible, but this is a single, unreplicated trial.

Magnitude: WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score fell 3.57 points vs 1.43 with placebo (between-group p < 0.001; confidence interval of the difference not reported); daily acetaminophen use fell by 267 mg in the yeast group (placebo change not reported; between-group p = 0.006).

Less Fatigue and Pain in Multiple Sclerosis ⭕️ Not Central to Health & Longevity

In 40 adults with multiple sclerosis (an autoimmune disease that damages nerve insulation) who completed a four-month placebo-controlled trial by Asghari (Tabriz), the yeast reduced fatigue and pain and improved several quality-of-life scores. This bears on symptom relief in multiple sclerosis rather than on the health and longevity of active adults. The trial comes from the same Tabriz group as the knee osteoarthritis study and has not been replicated.

Magnitude: FSS (Fatigue Severity Scale) score fell 5.55 points vs 2.35 with placebo, and VAS (visual analogue scale, a 0–10 pain rating) pain fell 1.15 vs 0.35 points (between-group p = 0.01 and 0.004; confidence intervals not reported).

Fewer Diarrhea Days in Tube-Fed Critically Ill Patients ⭕️ Not Central to Health & Longevity

In 128 critically ill tube-fed patients across 11 French intensive care units, Bleichner found fewer days with diarrhea than with placebo. This bears on hospital nutrition care rather than on the health and longevity of active adults, and the trial was co-authored by Biocodex scientist H. Bléhaut. The same setting carries the highest fungemia risk.

Magnitude: Diarrhea on 14.2% vs 18.9% of feeding days with placebo (OR (odds ratio, a comparison of odds between groups) 0.67; 95% CI 0.50–0.90).

Prevention of Necrotizing Enterocolitis in Preterm Infants ⭕️ Not Central to Health & Longevity ⚠️ Conflicted

In preterm infants, a meta-analysis of 10 trials found less necrotizing enterocolitis (life-threatening bowel inflammation in premature babies) and feeding intolerance. Yet the two largest trials, by Demirel and Serce in Turkey, each found no reduction. It bears on newborn intensive care, not adult health and longevity. Net reading: a pooled signal that the largest single trials did not confirm.

Magnitude: RR 0.56 (95% CI 0.36–0.89) across 10 trials with 1,264 infants; no difference in death (RR 1.12; 95% CI 0.46–2.70).

Low 🟩

Shorter Acute Infectious Diarrhea ⚠️ Conflicted

In children with gastroenteritis, a 29-trial meta-analysis found diarrhea shortened by about a day, rating the evidence very low quality. A Cochrane review found probiotics overall made no difference in low-bias trials, with S. boulardii subgroups equally inconsistent. Net reading: any effect is small and uncertain.

Magnitude: Diarrhea 1.06 days shorter than with placebo or no treatment (95% CI 0.79–1.32 days; 23 trials, 3,450 children).

Faster Recovery From Intestinal Parasite Infections ⚠️ Conflicted

Added to antiparasitic drugs, the yeast shortened amoebic bloody diarrhea in trials by Mansour-Ghanaei (adults) and Dinleyici (children), and cleared Giardia lamblia (a gut parasite) in Besirbellioglu’s adults. The largest amoeba trial, by Savaş-Erdeve (85 children), found no benefit. Net reading: possible faster recovery, not consistently confirmed.

Magnitude: Diarrhea lasted 12.0 vs 48.0 hours with antiparasitic therapy alone, and parasite cysts (dormant parasite forms) remained at 4 weeks in 0% vs 18.5% (p < 0.0001 and p < 0.02; no confidence interval reported; Mansour-Ghanaei 2003); Giardia cysts remained at 4 weeks in 0% vs 17.1% with metronidazole plus placebo (no confidence interval reported; Besirbellioglu 2006); median diarrhea 4.5 vs 5 days in the largest amoeba trial (p = 0.965; Savaş-Erdeve 2009).

Fewer Clostridioides difficile Recurrences ⚠️ Conflicted

Added to the antibiotics vancomycin or metronidazole, the yeast cut C. difficile recurrences in trials by McFarland and Chitapanarux, but a Surawicz trial found benefit only with high-dose vancomycin. For preventing first adult infections, pooled trials showed no significant effect. Net reading: possible benefit against recurrence, unproven for prevention.

Magnitude: Recurrence RR 0.43 (95% CI 0.20–0.97) vs placebo (McFarland 1994); 1.7% vs 13.1% with placebo (Chitapanarux 2025); 16.7% vs 50% with placebo, high-dose vancomycin group only (Surawicz 2000); adult prevention RR 0.80 (95% CI 0.47–1.34).

Maintenance of Crohn’s Disease Remission ⚠️ Conflicted

A small Guslandi trial (32 patients, added to mesalamine, an anti-inflammatory bowel drug) reported fewer relapses of Crohn’s disease (chronic inflammatory bowel disease), but the larger placebo-controlled Bourreille trial (165 patients, one year) found none. Net reading: no reliable effect on relapse.

Magnitude: Relapse in 47.5% vs 53.2% with placebo at 52 weeks (not significant; Bourreille 2013); 6.25% vs 37.5% in the smaller Guslandi trial.

Remission of Mild Ulcerative Colitis Flares

In 25 patients with mild-to-moderate flares of ulcerative colitis (chronic inflammation of the colon lining), adding 250 mg three times daily to mesalamine for 4 weeks was followed by remission in most completers (Guslandi 2003). Without a control group, improvement from mesalamine or natural course cannot be excluded.

Magnitude: Clinical remission in 17 of 24 completers after 4 weeks, confirmed by endoscopy (no control group).

Improved Heart Function in Heart Failure ⚠️ Conflicted

In heart failure with weak pumping, a small pilot trial by Costanza (Niterói) reported improved ejection fraction (the share of blood the heart pumps per beat). The larger multicenter GutHeart trial by Awoyemi (Oslo) found no change after three months. Net reading: no reliable effect on heart function.

Magnitude: Ejection fraction difference vs standard care alone of −0.2 percentage points (95% CI −2.2 to 1.9) at 3 months (GutHeart, 151 patients across three arms; Awoyemi 2021).

Speculative 🟨

Lower Body Fat ⚠️ Conflicted

The yeast reduced body and liver fat in obese mice (Everard 2014). In 25 obese adults, the yeast plus superoxide dismutase (antioxidant enzyme) produced no fat loss versus placebo (Rondanelli 2021). Net reading: animal-only support.

Tighter Gut Barrier

In Crohn’s disease patients in remission, the yeast improved a sugar-absorption test of gut leakiness (Garcia Vilela 2008). This marker is unvalidated against outcomes, and healthy adults were not studied.

Lower Blood Cholesterol and Remnant Lipoproteins

Strain CNCM I-1079 lowered remnant lipoprotein particles (cholesterol-rich fat-transport leftovers), an unvalidated marker, in 11 uncontrolled adults (Ryan 2015), without changing standard cholesterol. Biocodex’s laboratories reported cholesterol lowering in hamsters (Girard 2014).

Benefit-Modifying Factors

  • Genetic factors: No genetic variants are known to modify benefit; the yeast is not metabolized by human enzymes, so drug-metabolism genes play no role.
  • Baseline biomarkers: Benefit tracks stool yeast levels: in recurrent C. difficile disease, patients with stool concentrations below 10⁴ cells per gram relapsed far more often (Elmer 1999). No routine blood marker predicts response.
  • Sex: No sex-based differences in benefit have been reported in trials or meta-analyses.
  • Baseline risk and conditions: Absolute benefit is largest where baseline diarrhea risk is high (multiple antibiotics, tube feeding); low-risk inpatients in the Ehrhardt trial gained nothing. In Crohn’s disease, a post hoc (unplanned) analysis favored nonsmokers (Bourreille 2013).
  • Age: Pooled protection against antibiotic diarrhea was similar in children and adults (RR 0.43 vs 0.49; Szajewska 2015), while trials limited to older adults (Lewis 1998, over 65; Pozzoni 2012) found no effect, relevant to the older end of the target range.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: harm data come from case reports, case series and hospital cohorts, while randomized trials, such as those pooled in a Cochrane pediatric review, recorded no excess of serious adverse events.

Medium 🟥 🟥

Fungemia and Invasive Yeast Infection in Vulnerable Patients

The live yeast can cross a damaged gut wall or contaminate central venous catheters, via hands or air when capsules are opened, causing fungemia that is occasionally fatal. A hospital cohort by Wombwell and an intensive-care outbreak study by Muñoz tie cases to product use, with intensive care and tube or intravenous feeding as the main risk factors in probiotic-linked cases (Vinayagamoorthy 2023). The French label contraindicates use with central venous catheters, critical illness or immunodeficiency. Cases in healthy outpatients are rare.

Magnitude: Fungemia in 18 of 16,404 hospitalized recipients (0.11%; 1.70 per 10,000 patient-days), with intensive-care stay raising risk (OR 6.55; 95% CI 2.28–18.87); the authors give no rate for non-recipients beyond stating that cases were restricted to recipients (Wombwell 2021). In the Muñoz outbreak, all 3 cases vs 2 of 41 unaffected controls had received the probiotic.

Low 🟥

Allergic and Hypersensitivity Reactions ⚠️ Conflicted

The French label lists urticaria (hives) as rare and anaphylaxis (severe allergic reaction) and angioedema (deep facial swelling) as very rare; a case report described a delayed gut reaction in a child. In a placebo-controlled trial, urticaria rates were similar. Net reading: rare reactions occur without excess in controlled data.

Magnitude: Not quantified in available studies. Case reports and post-marketing frequency categories lack a comparison group, and the placebo-controlled trial’s abstract states only that urticaria was similar between groups.

Constipation and Mild Digestive Symptoms ⚠️ Conflicted

The label lists constipation at unknown frequency, and 22% of yeast-only patients had flatulence or loose stools in an open-label trial. Pooled H. pylori trials versus therapy alone (Zhou) showed less constipation. Net reading: mild symptoms occur, but controlled data show no excess.

Magnitude: Constipation RR 0.37 (95% CI 0.23–0.57) vs eradication therapy alone (Zhou 2019); flatulence or diarrhea in 22% on the yeast alone, with no rate for the same events reported in the metronidazole-alone group, which instead had epigastric (upper-abdominal) burning or constipation in 53% (García-Collinot 2020).

Speculative 🟨

Risk-Modifying Factors

  • Genetic factors: No pharmacogenetic variants affect the yeast. Rare inherited defects in antifungal immunity, such as CARD9 deficiency (a gene needed for immune signaling against fungi), theoretically raise fungemia risk.
  • Baseline biomarkers: A low neutrophil count (neutropenia) signals immunodeficiency, which the French label lists as a contraindication because of fungemia risk.
  • Sex: No sex differences in adverse events have been reported.
  • Pre-existing conditions: Intensive care and tube or intravenous feeding were the leading factors in probiotic-linked fungemia, and diabetes appeared in 13% of cases (Vinayagamoorthy 2023); central venous catheters and immunodeficiency are label contraindications (French label).
  • Age: A Belgian series (Poncelet 2021) found fungemia in three people aged 80 or older without catheters or intensive care and proposed older age as a contraindication.

Key Interactions & Contraindications

  • Oral and systemic antifungals (fluconazole, itraconazole, nystatin, amphotericin B): Avoid (label). The French label says not to combine them, as they kill the yeast and abolish its effect. Mitigation: the antifungal course is completed first.
  • Antibacterial antibiotics (ampicillin, amoxicillin-clavulanate, vancomycin, metronidazole): No adverse interaction; no monitoring needed. Ampicillin raised fecal yeast levels about 2.4-fold (Klein 1993), and amoxicillin-clavulanate plus yeast caused fewer side effects than the antibiotic alone (Kabbani 2017).
  • Miglustat (enzyme-inhibiting drug for rare lipid-storage disorders): No interaction; no monitoring needed. A randomized trial found unchanged miglustat blood levels with the yeast, and diarrhea days were numerically lower (Remenova 2015).
  • Immunosuppressants (tacrolimus, mycophenolate, high-dose prednisone, cancer chemotherapy): Avoid (label, immunodeficiency contraindication). Consequence: risk of fungemia, occasionally fatal. Mitigation: use is deferred until immune function recovers.
  • Over-the-counter antidiarrheals and acid reducers (loperamide, omeprazole, antacids): No interaction expected (theoretical); no study exists. Loperamide-simethicone outperformed the yeast head to head for symptom relief (Cottrell 2015), but the two were not combined.
  • Antifungal supplements (caprylic acid, oregano oil, undecylenic acid): Caution (theoretical). They may reduce yeast viability and benefit. Mitigation: they are used in separate courses rather than together.
  • Additive supplements (psyllium, bacterial probiotics such as Lactobacillus rhamnosus GG): Monitor (theoretical additive effect on stool form). Psyllium was co-administered without reported problems in an irritable bowel trial; pairing with bacterial probiotics is common but untested.
  • Hot, iced or alcoholic drinks: Avoid mixing (label). Liquids above 50 °C, iced or alcoholic weaken the live yeast, reducing effect. Mitigation: powder is mixed into room-temperature water or food.
  • Central venous catheters in nearby patients: Caution (label). Opening capsules near catheterized patients can contaminate their lines (Cassone 2003). Mitigation: capsules stay closed near such patients, and hands are washed after handling.

Populations who should avoid S. boulardii:

  • People with a central venous catheter (French label)
  • Critically ill or intensive-care patients (French label)
  • Immunodeficient people (French label; no specific condition or neutrophil threshold given)
  • People with hypersensitivity to the yeast or capsule ingredients (French label)
  • Older adults, proposed by Poncelet 2021 after fungemia in three patients aged 80 or older without other risk factors (no age threshold given)
  • Pregnant women, as a precaution because exposure data are insufficient (French label)
  • People with hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption (rare inherited disorders of milk-sugar digestion), for lactose-containing products such as Ultra-Levure (French label)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Screening for catheters and immune status: Prevents fungemia; the French label contraindicates use with a central venous catheter, critical illness or immunodeficiency.
  • Closed capsules near vulnerable people: Prevents airborne or hand-borne catheter contamination (French label); hands are washed after handling powder.
  • Stopping at unexplained fever: Fever is often the presenting sign of yeast fungemia (French label); stopping the product and drawing fungal blood cultures limits progression.
  • Separation from antifungal courses: Prevents loss of effect; the yeast is started after the antifungal ends.
  • Gradual start: Limits bloating or constipation; 250 mg once daily for 2–3 days before moving to twice daily.
  • Stopping at signs of allergy: Hives, facial swelling or breathing difficulty signal hypersensitivity, which can progress to anaphylaxis; stopping and urgent care prevent escalation.
  • Extra scrutiny after age 80: Reduces fungemia risk in frail older adults (Poncelet 2021), especially around hospital admission.

Therapeutic Protocol

Timing, titration and duration details without a citation reflect common practice.

  • Standard dose: 250 mg (about 5 billion CFU, colony-forming units, the count of live cells) twice daily, as in the Ehrhardt and Kotowska trials; the French Ultra-Levure label gives 200 mg once daily.
  • Antibiotic courses: Trials started the yeast within 24–48 hours of the first antibiotic dose and continued it for 7 days after the last (Ehrhardt 2016; Pozzoni 2012).
  • Clostridioides difficile recurrence: 1 g daily for 4 weeks alongside vancomycin or metronidazole (McFarland 1994); Chitapanarux 2025 used 500 mg every 12 hours with vancomycin for 10 days.
  • Helicobacter pylori therapy: 5–10 billion CFU daily for 10–14 days alongside eradication therapy (Chang 2026).
  • Travel: 250 mg or 1,000 mg daily during travel (Kollaritsch 1993); Life Extension’s microbiome protocol cites 5–10 billion CFU daily; Life Extension sells probiotic supplements.
  • Guideline approach: The American Gastroenterological Association conditionally suggests the yeast for preventing C. difficile during antibiotics (Su 2020); its members earn no revenue from probiotic sales.
  • Integrative approach: Practitioners such as Chris Kresser recommend it during and after antibiotics, and Michael Ruscio, who sells a product, uses it for small intestinal bacterial overgrowth.
  • Time of day: No trial compared timing; doses are taken with or between meals, avoiding liquids above 50 °C, iced or alcoholic (French label).
  • Half-life: No classical half-life; the yeast clears from stool 2–5 days after the last dose (French label), so effects stop quickly.
  • Single vs split doses: Most trials split the daily amount into two doses; the French label uses one daily dose; no trial compared schedules.
  • Genetic factors: No pharmacogenetic variants, such as those in CYP enzymes (liver enzymes that break down drugs), affect dosing, because human enzymes do not metabolize the yeast.
  • Sex differences: None reported; dosing is identical for women and men.
  • Age: The adult dose is the same across ages; a trial in adults over 65 (Lewis 1998) found no antibiotic-diarrhea benefit, and a series reported fungemia in three people aged 80 or older without other risk factors (Poncelet 2021).
  • Baseline biomarkers: No blood marker guides dose; low stool yeast concentrations predicted relapse in recurrent C. difficile disease (Elmer 1999), supporting full dosing.
  • Pre-existing conditions: Immunodeficiency, catheters or critical illness preclude use (French label); irritable bowel trials (Choi 2011; Abbas 2014) enrolled diarrhea-predominant or mixed types, not constipation-predominant.

Discontinuation & Cycling

  • Short-term vs lifelong: Use is typically course-based, matched to the antibiotic course plus 7 days, 10–14 days of H. pylori therapy or 4 weeks after C. difficile; continuous use for 52 weeks was well tolerated in the Bourreille trial.
  • Withdrawal effects: None reported; the yeast simply clears from stool within 2–5 days (French label).
  • Tapering: Not needed, because there is no dependence or rebound.
  • Cycling: No evidence supports cycling; the yeast does not colonize, so any effect ends shortly after stopping and resumes on restarting.

Sourcing and Quality

  • Strain identity: Most clinical evidence uses strain CNCM I-745 (Florastor, Enterol, Perenterol, Ultra-Levure; Biocodex). Other strains, such as CNCM I-1079, have far less clinical data, so the strain number on the label matters.
  • Viable cell count: Better labels state live-cell counts (CFU) guaranteed through expiry rather than at manufacture; trials commonly used about 5 billion CFU per 250 mg.
  • Third-party testing: ConsumerLab independently tested Florastor and Jarrow Formulas Saccharomyces Boulardii + MOS within its probiotic review; certification marks from USP (United States Pharmacopeia) or NSF (an independent product-certification body) also indicate verification.
  • Formulation and storage: The yeast is freeze-dried for room-temperature stability; the French label specifies storage below 25 °C away from humidity. Capsules and sachets are equivalent; some products contain lactose.
  • Reputable brands: Florastor (Biocodex) carries most trial data; Jarrow Formulas and Thorne (Sacro-B) are widely used supplement brands with S. boulardii products.

Practical Considerations

  • Time to effect: Prevention works only when started with the antibiotic; acute diarrhea benefit appears within 1–2 days; irritable bowel quality-of-life gains were measured at 4–6 weeks (Choi 2011; Abbas 2014).
  • Common pitfalls: Starting only after diarrhea begins, taking it with antifungals, stirring powder into hot drinks, using unstudied strains, and assuming bacterial-probiotic evidence applies to a yeast.
  • Regulatory status: A French non-prescription medicine whose summary of product characteristics says its antidiarrheal efficacy “has not been documented by controlled trials”; in the US, many probiotics are dietary supplements needing no Food and Drug Administration approval (National Center for Complementary and Integrative Health).
  • Guideline positions: ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition) strongly recommends it to prevent antibiotic diarrhea in at-risk children (Szajewska 2016); its pediatric gastroenterologist members earn no revenue from probiotic sales.
  • Payer incentives: Being cheap and off-patent, the yeast gives insurers no reason to resist it, but it also gives no company other than its main manufacturer a strong incentive to fund large trials.
  • Cost and access: Inexpensive and widely available without prescription.

Interaction with Foundational Habits

  • Sleep: No interaction (none studied). No trial measured sleep; any effect would be indirect, through relief of nighttime digestive symptoms.
  • Nutrition: Indirect. Live yeast is weakened by liquids above 50 °C, iced or alcoholic (French label), so doses go into room-temperature water or food. Fiber such as psyllium was combined safely in an irritable bowel trial; some products contain lactose.
  • Exercise: None. In a small randomized trial, the yeast did not change gains in sprint power from two weeks of interval training (Hudson 2025); exercise-related gut symptoms were not studied, and timing around workouts is unconstrained.
  • Stress management: None on anxiety or cortisol; possibly potentiating the heart-rate response. Before an exam, strain CNCM I-1079 left anxiety and salivary cortisol unchanged in medical students but raised pulse more under stress (Karbownik 2020); better irritable bowel quality of life (Choi 2011) may indirectly ease stress.

Monitoring Protocol & Defining Success

Before starting, a baseline check confirms the absence of a central venous catheter, recent intensive-care admission and immunosuppressive treatment. A complete blood count with differential is drawn for anyone with possible immune compromise. People using the yeast for a specific indication record their baseline stool pattern and, where relevant, have confirmatory tests, such as a urea breath test for H. pylori.

Ongoing monitoring follows a simple cadence: daily symptom and temperature awareness during each course, a stool review at 1–2 weeks, and indication-specific retesting at the end of treatment, such as a breath test at least 4 weeks after H. pylori therapy. Any unexplained fever during use triggers immediate blood cultures. For long-term use, a review every 3–6 months checks whether stool, bloating or quality-of-life goals are being met.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Complete blood count with absolute neutrophil count 1.5–8.0 × 10⁹/L (standard reference range) Safety check: low counts signal immunodeficiency, a contraindication Baseline only for people at risk of immune compromise; no fasting needed
Blood cultures (fungal) No established target; track whether any yeast grows Safety check: positive culture means stopping use Only if unexplained fever develops during use; drawn before antifungals start
Stool Clostridioides difficile toxin or PCR No established target; track a positive result during new diarrhea Expected to change: recurrence is what the yeast aims to prevent Only for new diarrhea during or after antibiotics; PCR (gene-detection test)
Helicobacter pylori urea breath test No established target; track conversion from positive to negative after therapy Expected to change: confirms eradication At least 4 weeks after therapy; acid suppressants paused 2 weeks before testing

Qualitative markers:

  • Stool frequency and form, tracked with the Bristol Stool Form Scale (a seven-point chart of stool types)
  • Bloating, abdominal pain and urgency
  • Overall digestive comfort and quality of life during and after antibiotic courses
  • New fever, chills or rash, which signal a possible adverse event

Emerging Research

  • Irritable bowel phase 3 trial: A Biocodex-sponsored, placebo-controlled trial in 406 adults (NCT07168434) measures symptom severity at 8 weeks; registered completion was October 2026, still listed as recruiting, no results posted. A positive result would extend the High irritable bowel quality-of-life item to symptom relief; a null would confine it to quality of life.
  • Small intestinal bacterial overgrowth vs rifaximin: A non-inferiority trial (testing whether it is no worse) in 222 patients (NCT07815548), not yet recruiting, completes in December 2027. Non-inferiority to the antibiotic rifaximin would firm up the Medium overgrowth item; failure would undercut it.
  • Microbiota during antibiotics: A Biocodex-sponsored phase 4 trial in 120 patients receiving amoxicillin for early Lyme disease (NCT06451913), recruiting until December 2026, measures gut microbiota change. A positive result would support the microbiota-buffering mechanism; a null would leave benefit resting on diarrhea outcomes alone.
  • Rescue Helicobacter pylori therapy: A 1,248-patient trial adding the yeast to a four-drug bismuth-based regimen after failed treatment (NCT07139366) had a registered completion of September 2026, is still listed as recruiting, with no results. A positive result would extend the High eradication item to rescue regimens; a null would confine it to first-line therapy.
  • Independent replication: The null Ehrhardt 2016 and Pozzoni 2012 trials contrast with pooled positive results, so large independent trials in adult outpatients could either confirm or overturn the High antibiotic-diarrhea grade.
  • Metabolic and joint effects: Animal data on fat and liver (Everard 2014) and a single knee-osteoarthritis trial (Dolatkhah 2024) need human replication before any longevity-relevant claim.
  • Engineered yeast: Researchers are modifying the yeast to deliver drugs in the gut, such as GLP-1-receptor-activating peptides (gut hormones regulating appetite and blood sugar) in mice (Hedin 2023).
  • Safety surveillance: Hospital cohorts such as Wombwell 2021 continue to define fungemia rates; larger registries could narrow or widen the groups for whom the yeast is unsuitable.

Conclusion

S. boulardii is a living yeast probiotic that, unlike bacterial probiotics, survives antibiotics. For health-focused adults, its clearest value is narrow and situational rather than a daily longevity tool. Across many trials it lowers the chance of diarrhea during antibiotic courses and modestly improves the success of treatment for the ulcer-causing stomach bacterium, although some large independent hospital studies found no protection. Smaller trials found better irritable bowel quality of life, without clearer symptom relief. Evidence for traveler’s diarrhea, bowel overgrowth and joint pain is promising but rests on few or single studies. Effects on chronic inflammatory bowel disease, heart failure and a dangerous hospital gut infection are mixed, and links to metabolism come mainly from animal work.

The main harm is a rare but serious bloodstream yeast infection, concentrated in people with intravenous catheters, critical illness or weakened immunity; for healthy adults the reported risks are mostly mild digestive effects and rare allergies.

The evidence base is large but uneven. Much early research came from groups working with the main manufacturer, and combined results lean on small trials of variable quality, whereas several larger independent studies were neutral. Medical societies that endorse it for defined uses do not profit from its sale, whereas a supplement publisher and a practitioner cited for dosing sell probiotic products. Overall, the yeast looks most useful as a short-term companion to antibiotics in people without risk factors for bloodstream yeast infection and offers little established benefit as a continuous health supplement.

Top - Benefits - Risks - Protocol